US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Stage

0.3754

0.0000

Volume:- -

Turnover:- -

Market Cap:10.85M

PE:-0.11

High:0.3754

Open:0.3754

Low:0.3754

Close:0.3754

52wk High:9.50

52wk Low:0.2700

Shares:28.91M

Float Shares:20.31M

Volume Ratio:- -

T/O Rate:- -

Dividend:0.05

Dividend Rate:13.32%

EPS(TTM):-3.3321

EPS(LYR):-3.1264

ROE:-44.60%

ROA:-3.54%

PB:0.07

PE(LYR):-0.12

Loading ...

Overview Company News Filings

Takeda Advances Oral Crohn’s Disease Drug TAK-279 With Active Mid-Stage Trial

Stoke Therapeutics Initiates Early-Stage Study for Genetic Vision Loss Treatment

MT Newswires Live

Lindian Resources Starts Second-Stage Resource Definition Drilling at Malawi Project

MT Newswires Live

Immatics’ treatment of Stage II and higher CM granted FDA orphan designation

Sally Beauty: Early-Stage Growth Initiatives and Margin Expansion Underpin Buy Rating and Raised $20 Price Target

Nuvation Bio Finalizes Protocol Amendment to Change Safusidenib Study From Mid-Stage to Late-Stage Trial

MT Newswires Live

Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy

Ucommune Shareholders Approve Major Capital Increase and Multi-Stage Reverse Split Plan

Mindarie’s Unconditional Cash Offer Sets Stage for Alpha Integrated REIT Shake-Up

Balanced Risk/Reward for Cloudflare: Strong AI-Driven Strategic Position Tempered by Premium Valuation and Early-Stage Monetization

Actinogen Raises Capital via Institutional Share Placement to Support Late-Stage Trials

Dreadnought Upgrades Mangaroon Gold Results, Sets Stage for Systematic Minga Bar Drilling

Advancing a Differentiated FcRn Pipeline: Late-Stage Catalysts and Solid Fundamentals Support Buy Rating on Immunovant

Valentine's Day Gifts for Every Stage of the Relationship -- WSJ

Amgen Advances Xaluritamig Into Early-Stage Trial for Hard-to-Treat Ewing Sarcoma

Dow Jones Rebounds as Tech Stocks Stage Recovery

Disney Leadership Shakeup Puts Parks And Content At Center Stage

Simply Wall St.

AGCO CEO Says Aging Farm Fleets Set Stage For Demand Pickup

Proven Senior Care Model Takes Center Stage at the Capitol

Syncona Posts Strong Q3 NAV Gains as Beacon Financing and Late‑Stage Pipeline Drive Outlook

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SSI/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"SSI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"SSI\",,,,,undefined,":{"symbol":"SSI","market":"US","secType":"STK","nameCN":"Stage","latestPrice":0.3754,"timestamp":1588968000000,"preClose":0.3754,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":20307519,"shares":28911336,"eps":-3.332056,"marketStatus":"Halted","change":0,"latestTime":"02-11 11:57:26 EST","open":0.3754,"high":0.3754,"low":0.3754,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.332056,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770843600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":998884800000,"exchange":"NYSE","adjPreClose":0.3754,"dividendRate":0.133191,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"SSI\",,,,,undefined,":{"symbol":"SSI","floatShares":20307519,"roa":"-3.54%","roe":"-44.60%","lyrEps":-3.1264,"shares":28911336,"dividePrice":0.05,"high":0.3754,"amplitude":0,"preClose":0.3754,"low":0.3754,"week52Low":0.27,"pbRate":"0.07","week52High":9.5,"institutionHeld":0.5253,"latestPrice":0.3754,"eps":-3.332056,"divideRate":0.133191,"volume":0,"delay":0,"ttmEps":-3.332056,"open":0.3754,"prevYearClose":8.12},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SSI\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-11-21","symbol":"SSI","fiscalQuarterEnding":"2019/10","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1574312400000,"reportTimeType":"pre","actualEps":-0.15},{"date":"2019-08-22","symbol":"SSI","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2019/07","expectedEps":null,"defaultRemindTime":1566460800000,"name":null,"time":"Pre-Market","dateTimestamp":1566446400000,"actualEps":-0.6},{"market":"US","date":"2019-05-23","symbol":"SSI","fiscalQuarterEnding":"2019/04","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1558584000000,"reportTimeType":"pre","actualEps":-1.67},{"market":"US","date":"2019-03-07","symbol":"SSI","fiscalQuarterEnding":"2019/01","expectedEps":0.73,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1551934800000,"reportTimeType":"pre","actualEps":0.25},{"market":"US","date":"2018-12-03","symbol":"SSI","amount":0.05,"name":"Stage Stores Inc","currency":"USD","type":"dividend","dateTimestamp":1543813200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SSI\",market:\"US\",,,undefined,":[{"executeDate":"2017-02-24","recordDate":null,"paymentDate":null,"value":0.15,"currency":"USD"},{"executeDate":"2017-05-25","recordDate":null,"paymentDate":null,"value":0.05,"currency":"USD"},{"executeDate":"2017-08-25","recordDate":null,"paymentDate":null,"value":0.05,"currency":"USD"},{"executeDate":"2017-11-27","recordDate":null,"paymentDate":null,"value":0.05,"currency":"USD"},{"executeDate":"2018-03-05","recordDate":null,"paymentDate":null,"value":0.05,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SSI\",market:\"US\",delay:true,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SSI\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610897952","title":"Takeda Advances Oral Crohn’s Disease Drug TAK-279 With Active Mid-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2610897952","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610897952?lang=en_us&edition=fundamental","pubTime":"2026-02-12 00:31","pubTimestamp":1770827515,"startTime":"0","endTime":"0","summary":"Takeda Pharmaceutical Company ($TAK) announced an update on their ongoing clinical study. Takeda (TAK) is running a mid-stage study called “A Phase...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/takeda-advances-oral-crohns-disease-drug-tak-279-with-active-mid-stage-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/takeda-advances-oral-crohns-disease-drug-tak-279-with-active-mid-stage-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI","BK4007","TAK"],"gpt_icon":0},{"id":"2610558199","title":"Stoke Therapeutics Initiates Early-Stage Study for Genetic Vision Loss Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2610558199","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610558199?lang=en_us&edition=fundamental","pubTime":"2026-02-11 22:12","pubTimestamp":1770819120,"startTime":"0","endTime":"0","summary":"Stoke Therapeutics  said Wednesday that the first patient has received a dose in an early-stage trial of STK-002 for the treatment of Autosomal Dominant Optic Atrophy, an inherited vision loss condition.The open-label study's primary objective will be to evaluate the safety and tolerability of the investigational medicine in patients between the ages of 6 and 55, the company said.Researchers plan to monitor changes in visual function, eye structure, and quality of life as secondary goals of the clinical program, the company added.Stoke Therapeutics said the trial is currently enrolling participants with a confirmed genetic mutation linked to the condition in Germany and the UK, with additional European sites expected to activate in the coming months.The company also said the dose escalation for the initial four groups is expected to continue through this year and into early next year.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SSI","LENZ","BK4139","BK4539","BK4007","STOK"],"gpt_icon":0},{"id":"2610704086","title":"Lindian Resources Starts Second-Stage Resource Definition Drilling at Malawi Project","url":"https://stock-news.laohu8.com/highlight/detail?id=2610704086","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610704086?lang=en_us&edition=fundamental","pubTime":"2026-02-11 08:14","pubTimestamp":1770768843,"startTime":"0","endTime":"0","summary":"Lindian Resources  started a second-stage resource definition drilling and mine geotechnical program at the Kangankunde project in Malawi to convert up to 40 million tonnes of current inferred mineral resource material to indicated category, according to a Wednesday filing with the Australian bourse.The program covers roughly 3,400 meters of diamond core drilling and 2,700 meters of reverse circulation drilling, with drilling expected to run through April, the filing said.Assay results are expected in May, with an updated resource model planned for June, per the filing.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LIN.AU","BK7095","SSI"],"gpt_icon":0},{"id":"2610527670","title":"Immatics’ treatment of Stage II and higher CM granted FDA orphan designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2610527670","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610527670?lang=en_us&edition=fundamental","pubTime":"2026-02-11 07:30","pubTimestamp":1770766213,"startTime":"0","endTime":"0","summary":"Immatics (IMTX)’ treatment of Stage II and higher cutaneous melanoma, in human leukocyte antigen-A 02:01-positive patients, was granted FDA orphan ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immatics-treatment-of-stage-ii-and-higher-cm-granted-fda-orphan-designation-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immatics-treatment-of-stage-ii-and-higher-cm-granted-fda-orphan-designation-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4207","BK4139","IMTX","SSI","CM"],"gpt_icon":0},{"id":"2610664234","title":"Sally Beauty: Early-Stage Growth Initiatives and Margin Expansion Underpin Buy Rating and Raised $20 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2610664234","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610664234?lang=en_us&edition=fundamental","pubTime":"2026-02-10 19:55","pubTimestamp":1770724532,"startTime":"0","endTime":"0","summary":"Analyst Susan Anderson of Canaccord Genuity maintained a Buy rating on Sally Beauty, boosting the price target to $20.00. Susan Anderson has given ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/sally-beauty-early-stage-growth-initiatives-and-margin-expansion-underpin-buy-rating-and-raised-20-price-target-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/sally-beauty-early-stage-growth-initiatives-and-margin-expansion-underpin-buy-rating-and-raised-20-price-target-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SBH","SSI"],"gpt_icon":0},{"id":"2610656513","title":"Nuvation Bio Finalizes Protocol Amendment to Change Safusidenib Study From Mid-Stage to Late-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2610656513","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610656513?lang=en_us&edition=fundamental","pubTime":"2026-02-09 22:04","pubTimestamp":1770645869,"startTime":"0","endTime":"0","summary":"Nuvation Bio  said Monday that it has finalized a protocol amendment to upgrade an ongoing study of its cancer drug, safusidenib, from a mid-stage to a late-stage trial.The expanded registrational study now includes patients with high-risk or high-grade IDH1-mutant astrocytoma who have completed standard care, the company said.Participant enrollment for the trial will increase from 100 to 300 patients across the US, China, and Australia, Nuvation Bio said.The updated protocol also introduces a new group to evaluate the treatment in patients with grade 3 IDH1-mutant oligodendroglioma who have not received chemotherapy or radiation, the company said.Shares of the company were up less than 1% in recent Monday premarket activity.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SSI","BK4007","NUVB"],"gpt_icon":0},{"id":"2610655338","title":"Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2610655338","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610655338?lang=en_us&edition=fundamental","pubTime":"2026-02-09 21:30","pubTimestamp":1770643800,"startTime":"0","endTime":"0","summary":"Outlines clinical and growth catalysts for ONP-002 in concussion and mild traumatic brain injury (mTBI) Fully prepared to initiate near-term clinical site onboarding and first patient dosing in Austra","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/09/3234525/0/en/Oragenics-Targets-Projected-9-Billion-Market-by-Advancing-First-and-Only-Clinical-Stage-Concussion-and-Mild-Traumatic-Brain-Injury-Therapy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OGEN","BK4139","CDC","IND","SSI"],"gpt_icon":0},{"id":"2610365823","title":"Ucommune Shareholders Approve Major Capital Increase and Multi-Stage Reverse Split Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2610365823","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610365823?lang=en_us&edition=fundamental","pubTime":"2026-02-09 20:57","pubTimestamp":1770641865,"startTime":"0","endTime":"0","summary":"Ucommune International ( ($UK) ) has provided an update. On 9 February 2026, Ucommune International Ltd held an extraordinary general meeting in Be...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ucommune-shareholders-approve-major-capital-increase-and-multi-stage-reverse-split-plan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ucommune-shareholders-approve-major-capital-increase-and-multi-stage-reverse-split-plan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI"],"gpt_icon":0},{"id":"2610658765","title":"Mindarie’s Unconditional Cash Offer Sets Stage for Alpha Integrated REIT Shake-Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2610658765","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610658765?lang=en_us&edition=fundamental","pubTime":"2026-02-09 20:42","pubTimestamp":1770640936,"startTime":"0","endTime":"0","summary":"Sabana Industrial REIT ( ($SG:M1GU) ) has shared an announcement. Mindarie Investment Pte. Ltd., advised by United Overseas Bank, has launched a ma...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mindaries-unconditional-cash-offer-sets-stage-for-alpha-integrated-reit-shake-up?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mindaries-unconditional-cash-offer-sets-stage-for-alpha-integrated-reit-shake-up?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SG","BK4209","REIT","SSI"],"gpt_icon":0},{"id":"2610550428","title":"Balanced Risk/Reward for Cloudflare: Strong AI-Driven Strategic Position Tempered by Premium Valuation and Early-Stage Monetization","url":"https://stock-news.laohu8.com/highlight/detail?id=2610550428","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610550428?lang=en_us&edition=fundamental","pubTime":"2026-02-09 09:45","pubTimestamp":1770601520,"startTime":"0","endTime":"0","summary":"Analyst Shrenik Kothari from Robert W. Baird maintained a Hold rating on Cloudflare and keeping the price target at $230.00. Shrenik Kothari has gi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/balanced-risk-reward-for-cloudflare-strong-ai-driven-strategic-position-tempered-by-premium-valuation-and-early-stage-monetization-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/balanced-risk-reward-for-cloudflare-strong-ai-driven-strategic-position-tempered-by-premium-valuation-and-early-stage-monetization-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XELB","BK4094","SSI"],"gpt_icon":0},{"id":"2610506513","title":"Actinogen Raises Capital via Institutional Share Placement to Support Late-Stage Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2610506513","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610506513?lang=en_us&edition=fundamental","pubTime":"2026-02-09 08:18","pubTimestamp":1770596298,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Actinogen Medical ( ($AU:ACW) ). Actinogen Medical has raised capital by issuing 269,833,333 new fully paid ord...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/actinogen-raises-capital-via-institutional-share-placement-to-support-late-stage-trials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/actinogen-raises-capital-via-institutional-share-placement-to-support-late-stage-trials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI"],"gpt_icon":0},{"id":"2610150352","title":"Dreadnought Upgrades Mangaroon Gold Results, Sets Stage for Systematic Minga Bar Drilling","url":"https://stock-news.laohu8.com/highlight/detail?id=2610150352","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610150352?lang=en_us&edition=fundamental","pubTime":"2026-02-09 06:08","pubTimestamp":1770588516,"startTime":"0","endTime":"0","summary":"Dreadnought Resources Limited ( ($AU:DRE) ) has issued an update. Dreadnought Resources Ltd is an Australian mineral exploration company focused on...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/dreadnought-upgrades-mangaroon-gold-results-sets-stage-for-systematic-minga-bar-drilling?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/dreadnought-upgrades-mangaroon-gold-results-sets-stage-for-systematic-minga-bar-drilling?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI"],"gpt_icon":0},{"id":"2609517229","title":"Advancing a Differentiated FcRn Pipeline: Late-Stage Catalysts and Solid Fundamentals Support Buy Rating on Immunovant","url":"https://stock-news.laohu8.com/highlight/detail?id=2609517229","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609517229?lang=en_us&edition=fundamental","pubTime":"2026-02-07 07:55","pubTimestamp":1770422120,"startTime":"0","endTime":"0","summary":"Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on Immunovant. The associated price target remains the same with $50.00. Sa...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/advancing-a-differentiated-fcrn-pipeline-late-stage-catalysts-and-solid-fundamentals-support-buy-rating-on-immunovant-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/advancing-a-differentiated-fcrn-pipeline-late-stage-catalysts-and-solid-fundamentals-support-buy-rating-on-immunovant-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI"],"gpt_icon":0},{"id":"2609513403","title":"Valentine's Day Gifts for Every Stage of the Relationship -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2609513403","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609513403?lang=en_us&edition=fundamental","pubTime":"2026-02-07 02:00","pubTimestamp":1770400800,"startTime":"0","endTime":"0","summary":"By Rachel Besser Perry | Photography by Elizabeth Arvelos Coetzee. The pressure is on to find the perfect Valentine's Day gift. What that is, exactly, will be different depending on where you are in your relationship. Are you one date in?Each stage comes with its own rules, and nothing ruins the mood faster than a gift that's too earnest too soon, or so generic it could have been purchased for anyone with a pulse.If your first date is on Valentine's Day, which is brave already, you may feel compelled to show up with something in hand. A gift at this stage should say, I have a sense of humor and no expectations. Think small, perishable, and plausibly ironic like a single excellent chocolate bar, a slim paperback with a clever premise, or a novelty that suggests taste rather than effort.Whether you're 29 or 68, three dates means you've cleared the basic hurdles: conversation flows, attraction is mutual, and neither of you has abruptly \"gotten busy\" for two weeks. At this stage, the best ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SSI"],"gpt_icon":0},{"id":"2609590013","title":"Amgen Advances Xaluritamig Into Early-Stage Trial for Hard-to-Treat Ewing Sarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2609590013","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609590013?lang=en_us&edition=fundamental","pubTime":"2026-02-07 00:33","pubTimestamp":1770395587,"startTime":"0","endTime":"0","summary":"Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen’s latest clinical update centers on a first‑in‑human Phase 1b study ti...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/amgen-advances-xaluritamig-into-early-stage-trial-for-hard-to-treat-ewing-sarcoma?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/amgen-advances-xaluritamig-into-early-stage-trial-for-hard-to-treat-ewing-sarcoma?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0868494617.USD","LU2242652126.USD","LU1061106388.HKD","BK4581","BK4585","SSI","BK4139","BK4533","LU0320765992.SGD","LU2112291526.USD","BK4599","LU1057294990.SGD","LU2089984988.USD","IE00BJT1NW94.SGD","IE0002141913.USD","BK4566","LU1023059063.AUD","LU1571399168.USD","IE00BJJMRZ35.SGD","LU2242646821.SGD","BK4534","LU0122379950.USD","AMGN","IE00BFTCPJ56.SGD","LU2468319806.SGD","IE00B2B36J28.USD","LU0058720904.USD","LU1983299246.USD","LU0109394709.USD","BK4588","IE0009355771.USD","IE00B4R5TH58.HKD","LU0889565916.HKD","SG9999001440.SGD","LU0289739699.SGD"],"gpt_icon":0},{"id":"2609594455","title":"Dow Jones Rebounds as Tech Stocks Stage Recovery","url":"https://stock-news.laohu8.com/highlight/detail?id=2609594455","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609594455?lang=en_us&edition=fundamental","pubTime":"2026-02-06 22:29","pubTimestamp":1770388165,"startTime":"0","endTime":"0","summary":"The Dow Jones (DJIA) is set to open Friday’s trading session higher, led by a recovery in tech stocks from a lengthy drawdown. All five tech stocks...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/dow-jones-rebounds-as-tech-stocks-stage-recovery?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/dow-jones-rebounds-as-tech-stocks-stage-recovery?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLK","SDOW","UDOW","DOG","MYMmain","SCHD","BK4588","DJX","DDM","DXD","DJIA","SSI","BK4585","DIA",".DJI","YMmain"],"gpt_icon":0},{"id":"2609158225","title":"Disney Leadership Shakeup Puts Parks And Content At Center Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=2609158225","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609158225?lang=en_us&edition=fundamental","pubTime":"2026-02-06 22:09","pubTimestamp":1770386954,"startTime":"0","endTime":"0","summary":"Walt Disney (NYSE:DIS) has appointed Josh D’Amaro, current head of its parks and experiences division, as its new CEO.\nDana Walden has been named President and Chief Creative Officer in a newly created C suite role.\nThis leadership transition ends prolonged uncertainty around Bob Iger’s succession and reshapes Disney’s top executive team.\n\nFor you as an investor, this marks a key moment for a company that spans theme parks, film studios, streaming, consumer products and TV networks...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/191564-main-header/1756254304645","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/191564-main-header/1756254304645"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/media/nyse-dis/walt-disney/news/disney-leadership-shakeup-puts-parks-and-content-at-center-s","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/media/nyse-dis/walt-disney/news/disney-leadership-shakeup-puts-parks-and-content-at-center-s","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1720051108.HKD","LU0786609619.USD","BK4550","LU1732799900.SGD","LU0251142724.SGD","LU1280957306.USD","LU0795875086.SGD","SG9999015978.USD","LU0640476718.USD","BK4585","LU0742534661.SGD","SSI","LU2347655156.SGD","LU1069347547.HKD","BK4532","LU2357305700.SGD","LU1035773651.USD","BK4561","LU1548497426.USD","LU0061475181.USD","LU0048573561.USD","BK4534","IE00B19Z3581.USD","BK4554","LU0708994859.HKD","LU1720051017.SGD","SG9999015945.SGD","LU1718418525.SGD","IE0002270589.USD","BK4588","LU0070217475.USD","IE00BZ1G4Q59.USD","LU0029864427.USD","LU1732800096.USD","LU1894683264.USD","LU0251131958.USD","LU1894683348.USD","LU0128525929.USD","BK4108","BK4551","LU0320765489.SGD","LU0210533765.USD","BK4507","SG9999015986.USD","LU0726765562.USD","DIS","LU2347655073.USD","LU0912757837.SGD","LU0795875169.SGD","LU2133065610.SGD"],"gpt_icon":1},{"id":"2609583585","title":"AGCO CEO Says Aging Farm Fleets Set Stage For Demand Pickup","url":"https://stock-news.laohu8.com/highlight/detail?id=2609583585","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609583585?lang=en_us&edition=fundamental","pubTime":"2026-02-06 02:33","pubTimestamp":1770316403,"startTime":"0","endTime":"0","summary":"AGCO Corp (AGCO) reported Q4 earnings beat and optimistic 2026 outlook despite weak demand. CEO Hansotia credits margin discipline.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/earnings/26/02/50425151/agco-ceo-says-aging-farm-fleets-set-stage-for-demand-pickup","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4152","LU1989763690.USD","LU2106854487.HKD","LU0471298777.SGD","LU2394011477.USD","LU0385154629.USD","LU1323610961.USD","LU2023250504.SGD","LU2211817866.USD","LU1974910355.USD","LU1721429741.USD","LU1721429402.USD","SSI","AGCO","LU2380233275.USD","LU1917777945.USD","LU2023250843.SGD","LU1989763427.SGD"],"gpt_icon":0},{"id":"2609054073","title":"Proven Senior Care Model Takes Center Stage at the Capitol","url":"https://stock-news.laohu8.com/highlight/detail?id=2609054073","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609054073?lang=en_us&edition=fundamental","pubTime":"2026-02-05 21:45","pubTimestamp":1770299100,"startTime":"0","endTime":"0","summary":"InnovAge PACE leaders and participants meet with lawmakers during critical budget yearDENVER, Feb.  05, 2026  (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge”) (Nasdaq: INNV), a leading Program ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/05/3233022/0/en/Proven-Senior-Care-Model-Takes-Center-Stage-at-the-Capitol.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SSI"],"gpt_icon":0},{"id":"2609329774","title":"Syncona Posts Strong Q3 NAV Gains as Beacon Financing and Late‑Stage Pipeline Drive Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2609329774","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609329774?lang=en_us&edition=fundamental","pubTime":"2026-02-05 15:38","pubTimestamp":1770277113,"startTime":"0","endTime":"0","summary":"The latest update is out from Syncona Shs GBP ( ($GB:SYNC) ). Syncona reported a solid third quarter, with net assets rising to £1.06bn and NAV per...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/syncona-posts-strong-q3-nav-gains-as-beacon-financing-and-late‑stage-pipeline-drive-outlook?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/syncona-posts-strong-q3-nav-gains-as-beacon-financing-and-late‑stage-pipeline-drive-outlook?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NAV","SSI"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}